ID 001008
Product name

Revaz AI

Revaz AI is the world’s first comprehensive clinical support tool that provides accurate, personalized risk and treatment outlooks for people with coronary artery disease (CAD). By predicting the risk of death and complications with different treatment options, Revaz helps both clinicians and patients make fast, personalized, and confident care decisions.
The problem you are solving

CAD is one of the leading causes of death worldwide, yet current tools are often outdated. About 1 in 5 treatment procedures do not work as they should, largely because clinicians must make individualized decisions using tools meant for broad populations. This can lead to greater health inequalities, worse health outcomes, and added strain on healthcare systems. Personalized heart care decisions can lead to better outcomes, higher quality care, and more efficient, sustainable health services.

Study Title (long)

Discovering Revaz AI CAD Insights and User Experience for Patients and Caregivers

Intended Use & Areas of Interest
  • Heart & Circulatory System
Brief description of how to use

We want your input on how Revaz can best support you, as a patient, family member, or caregiver. As we develop Revaz, we are eagerly inviting patient partners to help ensure its features meet real-world needs. Participants will be asked to share feedback on user experiences, desired features, and feature usefulness. For clinicians and health systems, Revaz easily integrates into existing clinical workflows through electronic medical records. It provides a clear, personalized risk report based on your unique health information. By analyzing data from many past patients, Revaz helps clinicians better understand complex cases and make decisions based on real-world evidence. Revaz is ethically trained and follows strict data privacy and security standards.

Seeking
  • Evaluators
  • Investors
Target Market

Canada and Outside Canada, ,

Exclusion Criteria

Age <18

Evaluation Period

05/10/2025 - 05/10/2026

Evaluator Sex & Age

Male Female Non-binary , From 18 to 120

Evaluator Compensation

0

Commitment of Evaluators

Take part in interviews, focus groups, or user experience testing to share your thoughts, needs, and preferences as a patient, family member, or caregiver.

Length of Follow-up (Months)

12

Story Inspiration

Coronary artery disease is a leading cause of death worldwide, but how we select treatment options is antiquated and can lead to poorer health outcomes, repeat procedures, and high care costs. We found this out through first hand experiences with family members with CAD and through our work with Cardiologists. This is why we decided to improve how we make decisions to treat CAD after a heart attack by creating Revaz AI. The first of its kind system to support personalized treatment decisions by leveraging artificial intelligence and health care data.